Daewoong gets nod for Nabota in UAE, Indonesia - (The Investor via NewsPoints Desk)

  • Daewoong Pharmaceutical announced that regulators in the United Arab Emirates (UAE) and Indonesia have approved Nabota for the treatment of frown lines, reported The Investor.

  • The company's partner Dansys Group will be in charge of sales of the product in the UAE, while a marketing partner for Indonesia has not yet been determined. 

  • Daewoong indicated that the botulinum toxin product would be launched in the countries during the first half of 2020. 

To read more NewsPoints articles, click here.

Reference Articles